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BACKGROUND: Cancer stem cells (CSCs) are considered a pivotal target for the eradication of hepatocellular
carcinoma (HCC). Recently, we reported that the CSC markers epithelial cell adhesion molecule (EpCAM) and
CD90 are expressed independently in primary HCCs and cell lines, and CD90+ cells share features of metastatic
vascular endothelial cells and express the vascular endothelial marker CD105, a co-receptor of transforming
growth factor-beta. METHODS: The EpCAM+ cell lines HuH1 and HuH7 were treated with 5-fluorouracil (5-FU) or
epirubicin in vitro. Gene and protein expression levels were evaluated by quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) and fluorescence-activated cell sorting, respectively. The expression of
CD105 in primary HCC was evaluated by immunohistochemistry. The relationship of CD105 expression status and
HCC prognosis was evaluated using 85 surgically resected HCC tissues by Kaplan–Meier survival analysis.
RESULTS: 5-FU or epirubicin treatment resulted in the generation of CD90+ and CD105+ cells in vitro in HuH1 and
HuH7 cells, which originally contain no CD90+ or CD105+ cells. This phenomenon was validated by qRT-PCR
analysis with activation of the epithelial-mesenchymal transition (EMT) program regulators Snail family zinc finger
1 (SNAI1) and SNAI2. Immunohistochemical analysis indicated that CD105+ cells were morphologically identical
to vascular endothelial cells in untreated primary HCCs. However, surgically resected specimens after
transcatheter arterial chemoembolization clearly indicated that CD105+ cancer cells survived at the peripheral
edge of the tumor. Kaplan–Meier survival analysis indicated that HCCs expressing CD105 showed poor prognosis
after surgery with statistical significance. CONCLUSIONS: Taken together, our data highlight the role of CD105+
HCC cells with activation of the EMT program generated de novo after cytotoxic therapy on the prognosis
of HCC patients.
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Hepatocellular carcinoma (HCC) is one of the most common
causes of cancer death worldwide [1], partially due to the lack of
effective chemotherapeutic options for patients with advanced-
stage disease [2]. Various molecular profiling approaches have
been applied to identify therapeutic targets specifically activated
in HCC [3]. Cancer stem cells (CSCs) are considered a pivotal
target for the eradication of HCC [4]. Some studies have suggested
the importance of evaluating stemness in HCC because it reflects
the malignant nature of the tumor closely and is related to poor
prognosis after surgery [5–8]. In HCC, several stem cell markers
including CD133, CD90, CD13, epithelial cell adhesion molecule(EpCAM), CD24, and side populations are reportedly enriched in CSC
populations [9].
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are expressed independently in primary HCCs and cell lines [10], and
CD90+ cells share features of metastatic vascular endothelial cells and
express the vascular endothelial marker CD105, a co-receptor of
transforming growth factor (TGF)-β [11]. Our previous data
suggested that CD105 is not only a vascular endothelial cell marker
but also a marker of CSCs with mesenchymal cell features, but the
significance of CD105 expression on HCC phenotypes remains to
be elucidated. In this study, we evaluated the expression of CD105
in human HCC and found that CD105+ HCC cells could be
generated from CD105− HCC cells de novo after treatment with
cytotoxic reagents with activation of the expression of the
epithelial-mesenchymal transition (EMT) inducers Snail family
zinc finger 1 (SNAI1) and SNAI2.Materials and Methods
Patients
HCC samples were obtained with informed consent from
patients who had undergone radical resection at the Department
of Gastroenterologic Surgery in Kanazawa University Hospital,
Kanazawa, Japan, and tissue acquisition procedures were ap-
proved by the Ethics Committee of Kanazawa University. A
total of 85 formalin-fixed and paraffin-embedded HCC samples
obtained from 2002 to 2008 were used for immunohistochemical
analyses.
Cell Culture and Reagents
The human liver cancer cell lines HuH1 andHuH7 were obtained
from the Japanese Collection of Research Bioresources (Osaka,
Japan) and routinely cultured with Dulbecco's modified Eagle's
medium supplemented with 10% FBS. Epirubicin and 5-
fluorouracil (5-FU) were obtained from Wako Pure Chemical
Industries, Ltd. (Tokyo, Japan) and Kyowa Kirin (Tokyo, Japan),
respectively. HuH1 and HuH7 cell lines were seeded at 10,000 cells
per well in a 6-well plate treated with epirubicin (0.5 μg/ml for
HuH1 and 0.1 μg/ml for HuH7) or 5-FU (2.0 μg/ml for HuH1 and
2.5 μg/ml for HuH7) for 5 days based on IC50 data obtained from a
cell proliferation assay. These cells were then used for quantitative
reverse transcription-polymerase chain reaction (qRT-PCR), fluorescence-
activated cell sorting (FACS), and immunofluorescence analyses, as
described previously [12].
qRT-PCR
Total RNA was extracted using TRIzol (Thermo Fisher Scientific
K.K., Yokohama, Japan) according to the manufacturer's instructions.
The expression of selected genes was determined in triplicate using the
7900 Sequence Detection System (Applied Biosystems, Foster City,
CA). Each sample was normalized relative to 18S rRNA expression. The
following probes were used: ENG, Hs00923996_m1; KRT19,
Hs00761767_s1; THY1, Hs00264235_21; and 18S rRNA,
Hs99999901_s1 (Applied Biosystems).
FACS
Cultured cells were trypsinized, washed, and resuspended in
Hank's balanced salt solution (Lonza, Basel, Switzerland) supple-
mented with 1% HEPES and 2% FBS. The cells were then incubated
with antibodies on ice for 30 minutes. Labeled cells were analyzed by
FACS using a FACSCalibur (BD Biosciences, San Jose, CA). Thefollowing antibodies were used: FITC-conjugated anti-EpCAM
monoclonal antibody Clone Ber-EP4 (DAKO, Carpinteria, CA),
APC-conjugated anti-CD326 (EpCAM) antibody (Miltenyi Biotec
K.K., Tokyo, Japan), FITC-conjugated anti-CD90 monoclonal
antibody Clone 5E10 (STEMCELL Technologies, Seattle, WA),
APC-conjugated anti-CD133/2 antibody Clone 293C3 (Miltenyi
Biotec K.K.), and APC-conjugated anti-CD105 mouse monoclonal
antibody (BD Biosciences).
Immunohistochemistry and Immunofluorescence
Immunohistochemistry was performed using Envision+ kits
(DAKO, Carpinteria, CA) according to the manufacturer's instruc-
tions. Anti-CD105 rabbit monoclonal antibody EPR10145 (Abcam,
Cambridge, UK) was used for detecting CD105. CD105 expression
was measured and categorized into two groups, CD105+ and
CD105−, according to the expression status not in vascular
endothelial cells but in cancer cells. Immunofluorescence was
performed using anti-CD105 mouse monoclonal antibody clone
SN6h (DAKO) and Alexa 488 FITC-conjugated anti-mouse IgG as
primary and secondary antibodies, respectively. Fluorescence micro-
scopic analysis was performed as described previously [6].
Statistical Analysis
Student's t test, chi-square test, and unpaired t test were performed
with GraphPad Prism software 5.0 (GraphPad Software, San Diego,
CA) to compare various test groups. Kaplan–Meier survival analysis
was also performed with GraphPad Prism software 5.0 (GraphPad
Software).
Results
De Novo Emergence of CD105+ HCC Cells after Treatment
with Cytotoxic Reagents
Previously, we evaluated the expression of the CSC markers
EpCAM and CD90 and their tumorigenicity in representative HCC
cell lines. We found that the EpCAM+ cell lines HuH1 and HuH7
do not express CD90 and show an epithelial cell shape with high
tumorigenic capacity, whereas the CD90+ cell lines HLE and HLF
also do not express EpCAM but show a mesenchymal cell shape with
high metastatic capacity. Interestingly, when we explored the
expression of CD105 in these cell lines, we identified the abundant
expression of CD105 in the CD90+ cell lines (89.2% in HLE and
57.2% in HLF) but not in the EpCAM+ cell lines (0% in HuH7 and
0.08% in HuH1) (Figure 1A), suggesting that CD105 may be a
marker of mesenchymal liver CSCs. Next, we evaluated the
expression of CD105 in the EpCAM+ cell lines HuH1 and HuH7
treated with the cytotoxic reagents epirubicin and 5-FU. Originally,
HuH1 and HuH7 cells contained a population of EpCAM+ cells
(33.3% in HuH1 and 66.9% in HuH7) but no CD90+ and CD105+
cells as evaluated by FACS analysis (Figure 1B). Furthermore, we
identified the enrichment of the EpCAM+ cell population after
treatment with epirubicin and 5-FU for 72 hours in HuH1 (39.4%
by epirubicin and 50.5% by 5-FU) and HuH7 cells (72% by
epirubicin and 82% by 5-FU), consistent with the highly
chemoresistant capacity of EpCAM+ CSCs. However, surprisingly,
we also identified a small population of CD90+ and CD105+ cells
generated de novo in HuH1 and HuH7 cells after treatment with
these cytotoxic reagents. When we evaluated the nuclear size of
HuH1 cells, we identified strong and modest increases of nuclear size








































































































































































Figure 1. FACS analysis of representative CSC markers. (A) Expression of CD105 in CD90+ (89.2% in HLE and 57.2% in HLF) and
EpCAM+ cell lines (0% in HuH7 and 0.08% in HuH1). (B) Expression of EpCAM, CD105, CD90, and CD133 in HuH1 and HuH7 cells treated
with DMSO, epirubicin, and 5-FU.
186 Mesenchymal Stem-Like CD105+ Cancer Cells Nomura et al. Translational Oncology Vol. 10, No. 2, 2017control, respectively (Figure 2A). We confirmed the de novo
expression of CD105 in HuH1 cells by immunofluorescence
(Figure 2A). The induction of genes encoding CD105 (ENG),CK19 (KRT19), and CD90 (THY1) was further confirmed by
qRT-PCR analysis in HuH1 and HuH7 cells (Figure 2B). The













































































































































































































Figure 2. De novo expression of CD105 in EpCAM+ CD90− CD105− HCC cell lines. (A) Immunofluorescence analysis of CD105
expression in HuH1 cells treated with DMSO, epirubicin, and 5-FU. (B) qRT-PCR analysis of ENG (encoding CD105), KRT19, THY1, SNAI1,
and SNAI2 in HuH1 and HuH7 cells treated with DMSO (white bar), epirubicin (black bar), and 5-FU (gray bar).
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transcription factors SNAI1 and SNAI2, master regulators of
genes regulating EMT. These data suggest that CD105,previously recognized as a vascular endothelial marker, was








































Figure 3. CD105 expression and prognosis in HCC. (A) Panel (a)
shows CD105 staining in vascular endothelial cells in HCC. Panel
(b) shows CD105 staining in HCC cells with a mesenchymal cell
shape. Panel (c) shows the enrichment of CD105+ cells in HCC
tissues surgically resected after treatment with epirubicin TACE.
(B). Kaplan–Meier survival analysis of CD105+ and CD105− HCCs
(overall survival [OS]). (C) Kaplan–Meier survival analysis of CD105+
and CD105− HCCs (recurrence-free survival [RFS]). CD105+ HCCs
showed poor RFS compared with CD105− HCCs with statistical
significance (P = .002).
Table 1. Clinicopathological Characteristics of CD105+ and CD105− HCC
Parameter CD105+ (n = 35) CD105− (n = 50) P Value
Age 62.2 ± 11.6 64.8 ± 9.1 .25
Sex (M/F) 26/9 36/14 1
Virus (HBV/HCV/HBV+HCV/NBNC) 14/21/0/0 12/33/2/3
LC (yes/no) 22/13 29/21 .82
Tumor size (N3 cm, ≦3 cm) 16/19 20/30 .66
AFP (median, [25%-75%]) 12.1 (10-418) 16 (10-92.5) .14
Microvascular invasion 16/19 8/42 .0036
Histological grade (well/moderate/poor) 3/25/7 8/38/4 .2
Distant organ metastasis (yes/no) 6/29 6/44 .54
TNM stages (I-II/III-IV) 25/10 38/12 .8
Edmondson-Steiner.
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Poor Prognosis
To elucidate the expression of CD105 in primary HCC tissues, we
immunohistochemically evaluated the expression of CD105 in a total
of 85 surgically resected HCC tissue samples. In most cases, CD105
staining was detected in vascular endothelial cells (Figure 3A, panel a);
however, we also detected CD105 staining in HCC cells with a
mesenchymal cell shape (Figure 3A, panel b). Most strikingly,
CD105+ cancer cells were detected in surgically resected HCC
patients' tissues who received transcatheter arterial chemoemboliza-
tion (TACE) with epirubicin prior to surgery (Figure 3A, panel c).
We classified the HCC cases into CD105+ and CD105− according
to the expression of CD105 in cancer cells, not in vascular endothelial
cells. We defined HCC as CD105+ even if we could detect only a
small subset of cancer cells (b1%) stained by the CD105 antibody,
unless the staining was restricted to vascular endothelial cells.
Accordingly, 35 of 85 HCCs were defined as CD105+. When we
evaluated the clinicopathological characteristics of the CD105+ and
CD105− HCCs, we could not detect any differences in terms of age;sex; virus infection status; presence of liver cirrhosis; tumor size;
serum alpha-fetoprotein values; histological grades; distant organ
metastasis; and tumor, node, and metastasis stages (See Table 1).
However, we found that CD105+ HCC could be characterized by a
high frequency of microvascular invasion of the tumor. Consistently,
although we could not detect differences in overall survival between
CD105+ and CD105−HCC cases, we observed the poor recurrence-free
survival of CD105+ HCCs compared with CD105− HCCs with
statistical significance (P = .002). These data suggest that the expression
of CD105 inHCC tissuesmay not only correlate with vascular density, as
reported previously [13], but also correlate with the abundance of cancer
cells with a mesenchymal cell shape expressing CD105, potentially
induced by cytotoxic reagents or activated by the EMT program.Discussion
Although considered monoclonal in origin, cancer cells are
heterogeneous in terms of morphology, proliferation, invasion
capacity, and drug resistance. This heterogeneity is currently
explained by two models: the clonal evolution model and the CSC
model [4]. Previously, we provided evidence that at least some HCCs
follow the CSC model [7]. We further explored the CSC hypothesis
using several CSC markers and found that liver CSCs can be divided
into at least two distinct entities: tumorigenic epithelial CSCs
expressing EpCAM and metastatic mesenchymal CSCs expressing
CD90 [10]. Besides, morphologically, CD90+ CSCs show vascular
endothelial cell features, which are closely correlated with the
phenotype termed vasculogenic mimicry [10]. Here, we provided
evidence that CD90+ CSCs also express the vascular endothelial
marker CD105. CD105+ HCC is characterized by a high frequency
of microvascular invasion and poor prognosis after surgery. CD105+
cancer cells were evident in HCC tissues previously treated by TACE,
suggesting that CD105+ cancer cells may be resistant to chemother-
apy and hypoxia. These findings suggest that CD105 may be a good
candidate molecule to target HCC cells with a capacity for vascular
invasion and resistance to cytotoxic reagents.
CD105 is a type I integral transmembrane glycoprotein that has
predominantly been investigated in the vasculature where it is
upregulated during angiogenesis [14]. In endothelial cells, CD105 is
an accessory co-receptor for TGF-β and associates at the cell surface with
type I and type II TGF-β receptors [14]. Therefore, CD105 has a key
role in modulating downstream signaling molecules such as SMAD
family proteins. Because of its role in neovascularization, CD105 is
generally considered as one of the vascular endothelial cell markers, such
as CD31 and VEGFRs, and reflects the vascular density of a tumor,
which may correlate with tumor progression, metastasis, and poor
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endothelial cells has been reported as a marker of invasiveness and
metastatic potential in cancer, including HCC [11].
Although CD105 is expressed in vascular endothelial cells and
strongly correlates with angiogenesis, recent studies suggested that
CD105 is also expressed in tumor epithelial cells of renal cell
carcinoma [15] and ovarian cancer [16]. Here, we reported that
CD105 is also expressed in liver CSCs expressing CD90 with
metastatic mesenchymal cell features. Furthermore, we provided
evidence that mesenchymal CD105+ cells could originate from
epithelial CD105− cells de novo. It may be possible that CD105 could
be a direct target against HCC with chemoresistance and metastatic
features. As CD105 is a co-receptor of TGF-β receptors, it is plausible
that TGF-β signaling may be activated in CD105+ HCC cells.
Indeed, we demonstrated the activation of SNAI1 and SNAI2 in
CD105+ HCC cells, potentially resulting from the activation of
TGF-β signaling. Therefore, it could be possible to suppress cancer
cell growth by TGF-β receptor signaling inhibitors such as
galunisertib (LY2157299) [17]. Furthermore, a recent phase II
study evaluating the effects of TRC105, a chimeric IgG1 anti-CD105
monoclonal antibody, in human HCC patients showed that it was
tolerated well [18]. Future studies are required to evaluate the role of
CD105+ cells and the therapeutic effects of galunisertib or TRC105
in human HCC.
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